Obesity Drugs Need Heart Studies, FDA Panel Says

Heart safety studies should be required for new obesity drugs, U.S. drug advisers said on Thursday, possibly adding a new hurdle to the drugs' approval. An advisory panel to the U.S. Food and Drug Administration voted 17-6 that regulators should make companies conduct heart impact studies in order to sell their drugs in the United States, even if clinical trials do not initially show evidence of increased heart risk.

Back to news